We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 20, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Deere (DE - Free Report) , Las Vegas Sands (LVS - Free Report) , Vertex (VRTX - Free Report) , Tesla (TSLA - Free Report) and Keurig Dr Pepper (KDP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Deere, Las Vegas Sands and Vertex
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Deere, Las Vegas Sands and Vertex. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Deere’s shares have gained +12% in the past year, outperforming the Zacks Farm Equipment industry, which has increased +10.2% over the same period. For fiscal 2019, Deere expects net sales to increase 5% year over year and net income at $3.3 billion.
Concerns stemming from the U.S-China trade war and lower commodity prices led to farmers getting cautious about their equipment purchases. However, the recently announced $16 billion aid program for American farmers impacted by the trade war is likely to bolster agricultural equipment sales, which bodes well for Deere.
Improving construction markets and the Wirtgen acquisition which has increased Deere's exposure to global transportation infrastructure will benefit results. Additionally, introduction of advanced technologies in its products will aid growth. However, raw material cost inflation, elevated expenses and unfavorable foreign currency impact remain near-term headwinds.
Shares of Las Vegas Sands have gained +0.6% over the past three months, underperforming the Zacks Gaming industry’s increase of +0.9%. This downside can be primarily attributed to trade was trade war between Beijing and Washington.
Increased revenues at casino, rooms and mall drove the company’s top line in first-quarter 2019. It generated solid revenues from Macao operations as well. In the next couple of years, it is likely to spend $2 billion in Macao.
To strengthen the resort portfolio, Las Vegas Sands is focusing on expanding the Four Seasons Tower Suites Macao, St. Regis Tower Suites Macao and the Londoner Macao. Planned investment in new capital projects in Macao and higher revenues from The Parisian Macao are also likely to drive growth. Nevertheless, high debt and competition are worrisome. Estimates for the current year have been revised upward over the past 60 days.
Vertex’s shares have outperformed the Zacks Biomedical and Genetics industry year to date (+7.4% vs. +5.2%). The Zacks analyst likes Vertex’s dominance in the CF market. A significant increase in the eligible patient population for its CF drugs is driving sales growth.
Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of CF revenues. Vertex will file a regulatory application for its VR-445 triple combination CF regimen this year, which is crucial for long-term growth as it has the potential to treat up to 90% of CF patients.
The company’s non-CF pipeline, though early stage, looks interesting with treatments being developed for sickle cell disease, thalassemia and pain. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs. Vertex’s dependence on just the CF franchise for growth is a concern.
Other noteworthy reports we are featuring today include Tesla and Keurig Dr Pepper.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
For Immediate Release
Chicago, IL – June 20, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Deere (DE - Free Report) , Las Vegas Sands (LVS - Free Report) , Vertex (VRTX - Free Report) , Tesla (TSLA - Free Report) and Keurig Dr Pepper (KDP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Deere, Las Vegas Sands and Vertex
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Deere, Las Vegas Sands and Vertex. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Deere’s shares have gained +12% in the past year, outperforming the Zacks Farm Equipment industry, which has increased +10.2% over the same period. For fiscal 2019, Deere expects net sales to increase 5% year over year and net income at $3.3 billion.
Concerns stemming from the U.S-China trade war and lower commodity prices led to farmers getting cautious about their equipment purchases. However, the recently announced $16 billion aid program for American farmers impacted by the trade war is likely to bolster agricultural equipment sales, which bodes well for Deere.
Improving construction markets and the Wirtgen acquisition which has increased Deere's exposure to global transportation infrastructure will benefit results. Additionally, introduction of advanced technologies in its products will aid growth. However, raw material cost inflation, elevated expenses and unfavorable foreign currency impact remain near-term headwinds.
Shares of Las Vegas Sands have gained +0.6% over the past three months, underperforming the Zacks Gaming industry’s increase of +0.9%. This downside can be primarily attributed to trade was trade war between Beijing and Washington.
Increased revenues at casino, rooms and mall drove the company’s top line in first-quarter 2019. It generated solid revenues from Macao operations as well. In the next couple of years, it is likely to spend $2 billion in Macao.
To strengthen the resort portfolio, Las Vegas Sands is focusing on expanding the Four Seasons Tower Suites Macao, St. Regis Tower Suites Macao and the Londoner Macao. Planned investment in new capital projects in Macao and higher revenues from The Parisian Macao are also likely to drive growth. Nevertheless, high debt and competition are worrisome. Estimates for the current year have been revised upward over the past 60 days.
Vertex’s shares have outperformed the Zacks Biomedical and Genetics industry year to date (+7.4% vs. +5.2%). The Zacks analyst likes Vertex’s dominance in the CF market. A significant increase in the eligible patient population for its CF drugs is driving sales growth.
Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of CF revenues. Vertex will file a regulatory application for its VR-445 triple combination CF regimen this year, which is crucial for long-term growth as it has the potential to treat up to 90% of CF patients.
The company’s non-CF pipeline, though early stage, looks interesting with treatments being developed for sickle cell disease, thalassemia and pain. However, competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs. Vertex’s dependence on just the CF franchise for growth is a concern.
Other noteworthy reports we are featuring today include Tesla and Keurig Dr Pepper.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.